We recently published a list of 12 Undervalued Defensive Stocks for 2025. In this article, we are going to take a look at ...

Ballentine Partners LLC boosted its holdings in shares of GSK plc (NYSE:GSK – Free Report) by 40.7% in the fourth quarter, ...

GlaxoSmithKline (GSK – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Graham Parry from ...

Jefferies analyst Peter Welford maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £14.50. The ...

British pharmaceutical company GSK on Monday said it had agreed to buy a US company that specialises in the treatment of rare gastrointestinal cancer GIST.

The anti-vaccine movement in the U.S. has gained momentum with President-elect Donald Trump's nomination of Robert F. Kennedy ...

Boston-based biotechnology firm developing therapy for treatment of gastrointestinal stromal tumors - Anadolu Ajansı ...

GSK plc (GSK) stock saw a decline, ending the day at $33.09 which represents a decrease of $-0.66 or -1.96% from the prior close of $33.75. The stock opened at $33.26 and touched a low of $33.01 ...

The first major deal of JPM 2025 will give GSK a promising small molecule drug for gastrointestinal stromal tumors.

And while Wood said the pharma still isn’t interested in joining the overcrowded obesity landscape, GSK is considering ways ...

Jemperli (dostarlimab) in combination with chemotherapy (carboplatin and paclitaxel) for first-line treatment of adult ...

J&J announces a big deal to acquire neuroscience company ITCI for $14.6 billion, while Lilly and GSK announce smaller deals.